GlassScriptPhysician profile
Sarah E Gough
NPI 1487089108
$5,248.31
in general payments reported to CMS, 2019-2025
31 companies · $442 in 2025
The $442 reported for 2025 was more than what 83% of Women'S Health (Nurse Practitioner) providers received nationally (typical 2025 total: $123).
See the full distribution for Women's Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,641 · 2022: $1,157 · 2023: $1,162 · 2024: $847 · 2025: $442.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,277 · Education: $174.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,276.85 |
| Education | $173.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $965.08 | 2021-2024 | |
| Mayne Pharma Commercial LLC | $593.60 | 2021-2025 | |
| Astellas Pharma US INC | $437.07 | 2023-2025 | Veozah, Myrbetriq |
| Daiichi Sankyo INC. | $434.00 | 2021-2022 | |
| Exeltis, USA INC. | $432.07 | 2021-2025 | Slynd |
| Shield Therapeutics INC | $377.94 | 2022-2025 | Accrufer |
| Evofem Biosciences, INC. | $264.86 | 2021-2023 | Phexxi |
| Pfizer INC. | $264.09 | 2022-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $205.98 | 2021-2025 | |
| Avanos Medical | $180.27 | 2021-2022 | |
| Avion Pharmaceuticals | $180.09 | 2021-2023 | Balcoltra |
| Coopersurgical, INC. | $141.43 | 2021 | |
| Myriad Women'S Health, INC. | $118.12 | 2023 | Myrisk |
| Sumitomo Pharma America, INC. | $109.94 | 2023-2025 | Myfembree, Gemtesa |
| Hologic Sales and Service, LLC | $56.21 | 2025 | Aptima, Thinprep 2000 Processor |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $54.86 | 2021-2024 | |
| Glaxosmithkline, LLC. | $52.61 | 2021-2022 | |
| Therapeuticsmd, INC. | $46.87 | 2021-2022 | |
| Urovant Sciences INC | $44.98 | 2022 | |
| Trevena, INC. | $41.60 | 2021 | |
| Scynexis, INC. | $34.82 | 2022 | |
| Sage Therapeutics, LLC | $29.49 | 2024-2025 | Zurzuvae |
| Lupin INC. | $27.35 | 2021 | |
| Merck Sharp & Dohme LLC | $27.17 | 2021-2024 | Gardasil 9, Gardasil, Vaxneuvance |
| Baxter Healthcare | $23.45 | 2022 | |
| Vertex Pharmaceuticals Incorporated | $21.76 | 2025 | |
| Roche Diagnostics Corporation | $20.80 | 2021 | |
| Axonics, INC. | $19.52 | 2023 | Axonics |
| Myovant Sciences INC. | $14.52 | 2022 | |
| Ascend Therapeutics US, LLC | $14.50 | 2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.26 | 2024 | Xifaxan |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarah Gough listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.